CGP can detect biomarkers at nucleotide-level resolution and typically comprises all major genomic variant classes (single nucleotide variants, indels, copy number variants, fusions, and splice variants). Additionally, CGP can detect genomic signatures such as TMB and MSI (tumor mutational burden and microsatellite instability, respectively), maximizing the ability to find clinically actionable alterations.
CGP consolidates biomarker detection into a single multiplex assay, eliminating the need for iterative testing. With a single test, you can simultaneously detect both common and rare biomarkers to increase the likelihood of identifying actionable alterations. This potentially provides faster results, limits the input of precious biopsy samples, and may reduce the risks and costs associated with rebiopsy.1,2
CGP can offer results for both actionable and potentially actionable biomarkers to help identify more effective therapeutic paths and innovative clinical trial options for cancer patients. When tissue biopsies are unavailable, CGP from liquid biopsy may provide helpful information about a tumor's genomic make-up. CGP using tissue and liquid biopsy together may reveal more insights into a tumor's composition.3,4
Multiple studies have demonstrated the ability of CGP to identify potentially clinically relevant genomic alterations, across different tumor types.
Potentially Actionable Variants Identified in Patient Samples | Patient Cohort |
---|---|
Single-center, prospective study with 339 patients. Refractory cancers, multiple types: ovarian (18%), breast (16%), sarcoma (13%), renal (7%), and others5 | |
Prospective study with 100 patients; diverse-histology, rare, or poor-prognosis cancers6 | |
Prospective study with 10,000 patients with advanced cancer across a vast array of solid tumor types7 | |
Retrospective study with 96 patients across multiple tumor types8 | |
6832 NSCLC patients9 |
The percent of actionable alterations identified in each study varies according to patient cohort, study type, CGP panel used, and criteria for categorizing a genomic alteration as actionable.
Data on file.
Discover how a single next-generation sequencing assay can reveal hundreds of actionable cancer biomarkers, reduce assay times, save valuable tissue samples, and transform lives. Whether you're a clinician or researcher, this guide can help you better understand cancer care with data-driven insights.
Single-gene assays are limited to a single biomarker. Many times these assays do not cover the entire gene sequence, with the risk of missing important gene alterations.11
An iterative single-gene testing approach can lead to tissue depletion and repeat biopsies.11,13,14
Targeted panels typically offer coverage of specific genes instead of the entire coding sequence. As a result, they can miss important alterations.7
A comprehensive single assay that assesses a wide range of biomarkers increases the chances of obtaining relevant information vs. targeted panels.
Not only can whole-exome sequencing be cost- prohibitive when developing personalized therapies, but it can also lead to inadequate coverage to detect important variants in lower frequencies due to the need for high amounts of sequencing.15-19
Integrating comprehensive genomic profiling into your lab’s in-house test menu can unlock a range of valuable advantages, including:
TruSight Oncology Comprehensive products are IVD test kits that enable genomic profiling based on DNA and RNA while consolidating multiple iterative tests into one.
Learn more about TruSight Oncology Comprehensive